Clinical and Echocardiographic Characteristics After Six Months of
Sacubitril Valsartan in Chagas Heart Disease.
Chagas cardiomyopathy is the most prevalent non-ischemic cardiomyopathy
in Latin America, with high morbidity and mortality even today.
Treatment of these patients is based on the use of medications for heart
failure. This study evaluated a cohort of patients with Chagas heart
disease who used sacubitril valsartan at a referral hospital for the
disease in Brazil. After six months, there was a symptomatic improvement
in these individuals assessed by the NYHA classification, with a 44.3%
reduction in the absolute number of patients classified as III-IV in the
period (p 0.035), but without changes in the parameters on the
echocardiogram for reverse ventricular remodeling and still high
mortality rate and hospitalization. These results emphasize the
importance of studying the use of sacubitril valsartan in chagas heart
disease to better describe its effectiveness taking into account the
peculiarities of these individuals.